71 results
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
to ensure compliance with applicable corporate governance requirements.
The majority of our current executive management do not have experience … with legally mandated corporate governance policies relative to our competitors whose management teams have more public company experience.
We rely
8-K
NBSE
NeuBase Therapeutics Inc
18 May 23
Departure of Directors or Certain Officers
4:05pm
, effective May 12, 2023. Dr. Ende served as a member of the Nominating and Corporate Governance Committee of the Board and the Compensation Committee
424B5
NBSE
NeuBase Therapeutics Inc
29 Dec 22
Prospectus supplement for primary offering
5:03pm
disadvantage and require our management to devote additional time and resources to ensure compliance with applicable corporate governance requirements … company, we may need to dedicate additional time and resources to comply with legally mandated corporate governance policies relative to our competitors
8-K
0g27sx
12 Sep 22
Submission of Matters to a Vote of Security Holders
4:47pm
8-K
EX-10.1
3qtqcfy is
12 Sep 22
Submission of Matters to a Vote of Security Holders
4:47pm
8-K
EX-99.1
21rl9for
5 Jan 22
NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors
4:03pm
8-K
prod4n6ns7wx0pn976h
5 Jan 22
NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors
4:03pm
424B5
urfq a34z0q6g26
27 Aug 21
Prospectus supplement for primary offering
5:21pm
8-K
hh0y5dvwq29
12 May 21
NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors
4:30pm
424B5
3bdgo0
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
c0x8r5an aw
21 Apr 21
Prospectus supplement for primary offering
4:03pm
8-K
z61zdg4kj3p2l4 qk
26 Mar 21
Departure of Directors or Certain Officers
5:02pm